PMID- 22168383
OWN - NLM
STAT- MEDLINE
DCOM- 20120515
LR  - 20171116
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 60
IP  - 3
DP  - 2012 Feb
TI  - Classical lobular breast carcinoma consistently lacks topoisomerase-IIalpha gene 
      amplification: implications for the tailored use of anthracycline-based 
      chemotherapies.
PG  - 482-8
LID - 10.1111/j.1365-2559.2011.04067.x [doi]
AB  - AIMS: There is consistent lack of data focusing the topoisomerase-IIalpha gene status 
      in lobular breast carcinoma, a subtype that usually shows poor responsiveness to 
      chemotherapies including those using anthracycline drugs. METHODS AND RESULTS: 
      Forty-six infiltrative lobular carcinomas, 13 with matched metastases, were used. 
      Topoisomerase-IIalpha gene amplification was evaluated by chromogenic in situ 
      hybridization (CISH) and fluorescence in situ hybridization (FISH). We also 
      assessed Her2/neu status by CISH, FISH and silver in situ hybridization (SISH). 
      HER2 immunoexpression was assessed by the HercepTest. Forty-four of 46 (95%) 
      cases revealed no topoisomerase-IIalpha amplification, whereas two of 46 (5%) cases 
      were amplified by all three techniques. Eleven of the 13 metastatic sites showed 
      no amplification either in the primary or in the metastases (85%); the remaining 
      two were amplified (15%). Her2/neu was not amplified in 44 of 46 (95%) cases nor 
      was it amplified in 11 of 13 (95%) metastatic tissues. The two cases showing 
      Her2/neu and topoisomerase-IIalpha amplification scored 3+; the remaining 
      non-amplified cases scored 0 or 1+ in 40 and 2+ in four cases. CONCLUSIONS: In 
      the era of personalized and tailored therapies, we suggest that patients affected 
      by the classical lobular subtype of breast carcinoma constantly lack the ad hoc 
      predictive rationale for receiving common chemotherapy that includes 
      anthracyclines.
CI  - (c) 2011 Blackwell Publishing Limited.
FAU - Brunello, Eleonora
AU  - Brunello E
AD  - Department of Pathology and Diagnostic, University of Verona, Italy.
FAU - Brunelli, Matteo
AU  - Brunelli M
FAU - Manfrin, Erminia
AU  - Manfrin E
FAU - Nottegar, Alessia
AU  - Nottegar A
FAU - Bersani, Samantha
AU  - Bersani S
FAU - Vergine, Marco
AU  - Vergine M
FAU - Molino, Annamaria
AU  - Molino A
FAU - Fiorio, Elena
AU  - Fiorio E
FAU - Chilosi, Marco
AU  - Chilosi M
FAU - Gobbo, Stefano
AU  - Gobbo S
FAU - Martignoni, Guido
AU  - Martignoni G
FAU - Bonetti, Franco
AU  - Bonetti F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111214
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Anthracyclines)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
SB  - IM
MH  - Anthracyclines/*therapeutic use
MH  - Antigens, Neoplasm/*genetics/metabolism
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/*genetics/pathology/therapy
MH  - Carcinoma, Lobular/*genetics/secondary/therapy
MH  - Chemotherapy, Adjuvant
MH  - DNA Topoisomerases, Type II/*genetics/metabolism
MH  - DNA, Neoplasm/analysis
MH  - DNA-Binding Proteins/*genetics/metabolism
MH  - Female
MH  - *Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Precision Medicine
MH  - Receptor, ErbB-2/genetics/metabolism
EDAT- 2011/12/16 06:00
MHDA- 2012/05/16 06:00
CRDT- 2011/12/16 06:00
PHST- 2011/12/16 06:00 [entrez]
PHST- 2011/12/16 06:00 [pubmed]
PHST- 2012/05/16 06:00 [medline]
AID - 10.1111/j.1365-2559.2011.04067.x [doi]
PST - ppublish
SO  - Histopathology. 2012 Feb;60(3):482-8. doi: 10.1111/j.1365-2559.2011.04067.x. Epub 
      2011 Dec 14.